New Multiple Myeloma Treatment in Development
A new trispecific antibody treatment for relapsed multiple myeloma is in development for patients.
Updated on Oct. 15, 2026 in Cancer
Live Poll
Should advanced practitioners be allowed to practice independently with the same scope as physicians?
Researchers have developed a new trispecific antibody, ramantamig, designed to treat relapsed or refractory multiple myeloma. This treatment, developed by Johnson & Johnson, aims to simplify care through outpatient dosing.
Why it matters
As the treatment landscape for multiple myeloma evolves, trispecific antibodies like ramantamig offer a novel approach to addressing resistant disease. By utilizing outpatient ramp-up dosing, this therapy seeks to reduce the geographic and logistical barriers that often complicate access for patients managing relapsed conditions.
Clinical trial results for the trispecific antibody ramantamig were presented following development for relapsed or refractory multiple myeloma. The reimbursement landscape shows 100% coverage for physician visits compared to 80% for those led by advanced practitioners, though long-term safety data remains unknown.
The players
Johnson & Johnson
A global pharmaceutical company that develops oncology treatments, including therapies for multiple myeloma.
Beth Faiman
A nurse practitioner whose career in clinical practice began in 2002.
The details
Ramantamig is a trispecific antibody designed to induce myeloma cell death by engaging CD3 while simultaneously targeting GPRC5D and B-cell maturation antigen (BCMA). By bringing these targets together via CD3 engagement, the drug facilitates an immune response against cancer cells. Patients receive the treatment through an outpatient ramp-up dosing schedule, which requires accompanying antiviral and anti-infection prophylaxis to manage immune system effects.
Timeline
2002: Beth Faiman began her clinical practice as a nurse practitioner.
October 2026: Clinical findings on trispecific antibodies were reported.
Health Landscape
The introduction of trispecific antibodies marks a significant shift from traditional treatments toward more targeted, multi-antigen engagement for relapsed multiple myeloma. These findings presented at the International Myeloma Society meeting build upon the ongoing evolution of antibody-based immunotherapy.
If you are managing relapsed or refractory multiple myeloma, discuss the current status of trispecific antibody therapies with your hematologist. Because this treatment requires specific prophylactic care, it is essential to review all safety protocols with your oncology team before starting any new regimen.
The takeaway
Ramantamig represents a novel trispecific approach to attacking multiple myeloma cells that could eventually simplify the delivery of care. Always consult your oncology team regarding the risks of prophylaxis and how new treatments may fit into your existing care plan.
Further reading
For more background on current research, visit our Cancer page.
Source note: This article includes information reported by Ajmc.
Live Poll
Should advanced practitioners be allowed to practice independently with the same scope as physicians?
